Chargement en cours...
Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors
Sorafenib, a multikinase inhibitor with antiproliferative, antiangiogenic, and proapoptotic properties, constitutes the only effective first-line drug approved for the treatment of advanced hepatocellular carcinoma (HCC). Despite its capacity to increase survival in HCC patients, its success is quit...
Enregistré dans:
| Publié dans: | Exp Mol Med |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group UK
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6185986/ https://ncbi.nlm.nih.gov/pubmed/30315182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s12276-018-0159-1 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|